{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:04:52Z","timestamp":1793239492257,"version":"4.5.0"},"reference-count":23,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1370,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1177\/0091270010389471","type":"journal-article","created":{"date-parts":[[2011,1,13]],"date-time":"2011-01-13T00:22:24Z","timestamp":1294878144000},"page":"1696-1703","source":"Crossref","is-referenced-by-count":37,"title":["Treatment With Liraglutide-a Once-Daily GLP-1 Analog-Does Not Reduce the Bioavailability of Ethinyl Estradiol\/Levonorgestrel Taken as an Oral Combination Contraceptive Drug"],"prefix":"10.1002","volume":"51","author":[{"given":"Lisbeth V.","family":"Jacobsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Vouis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Hindsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Zdravkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,12]]},"reference":[{"key":"10.1177\/0091270010389471-BIB1|cit1","unstructured":"European Medicines Agency (EMA). Summary of product characteristics-Victoza http:www.ema.europa.eudocsenGBdocumentlibraryEPAR-ProductInformationhuman001026WC500050017.pdf"},{"key":"10.1177\/0091270010389471-BIB2|cit2","unstructured":"Food and Drug Administration (FDA). Victoza prescribing information http:www.accessdata.fda.govdrugsatfdadocslabel2010022341lbl.pdf"},{"key":"10.1177\/0091270010389471-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1021\/jm9909645","article-title":"Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration","volume":"43","author":"Knudsen","year":"2000","journal-title":"J Med Chem"},{"key":"10.1177\/0091270010389471-BIB4|cit4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1464-5491.2009.02666.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)","volume":"26","author":"Marre","year":"2009","journal-title":"Diabet Med"},{"key":"10.1177\/0091270010389471-BIB5|cit5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1177\/0091270010389471-BIB6|cit6","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","article-title":"Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): randomised, 52-week, phase III, double-blind, parallel-treatment trial","volume":"373","author":"Garber","year":"2009","journal-title":"Lancet"},{"key":"10.1177\/0091270010389471-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc08-2124","article-title":"Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD)","volume":"32","author":"Zinman","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1177\/0091270010389471-BIB8|cit8","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","article-title":"Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU)","volume":"52","author":"Russell-Jones","year":"2009","journal-title":"Diabetologia"},{"key":"10.1177\/0091270010389471-BIB9|cit9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label study (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"key":"10.1177\/0091270010389471-BIB10|cit10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00125-001-0719-z","article-title":"The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men","volume":"45","author":"Agers\u00f8","year":"2002","journal-title":"Diabetologia"},{"issue":"5","key":"10.1177\/0091270010389471-BIB11|cit11","first-page":"E981","article-title":"Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans","volume":"273","author":"Nauck","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1177\/0091270010389471-BIB12|cit12","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","article-title":"Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study","volume":"359","author":"Zander","year":"2002","journal-title":"Lancet"},{"issue":"suppl 1","key":"10.1177\/0091270010389471-BIB13|cit13","first-page":"A593","article-title":"The effect of the once-daily human GLP-1 analogue liraglutide on the pharmacokinetics of paracetamol","volume":"57","author":"Kapitza","year":"2008","journal-title":"Diabetes"},{"issue":"suppl 1","key":"10.1177\/0091270010389471-BIB14|cit14","first-page":"A130","article-title":"A randomised, doubleblind, cross-over trial investigating the effect of liraglutide on the absorption pharmacokinetics of concomitantly administered oral drugs in healthy subjects","volume":"57","author":"Malm-Erjef\u00e4lt","year":"2008","journal-title":"Diabetes"},{"key":"10.1177\/0091270010389471-BIB15|cit15","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0010-7824(99)00040-2","article-title":"Low dose oral contraceptives and quality of life","volume":"59","author":"Egarter","year":"1999","journal-title":"Contraception"},{"issue":"144","key":"10.1177\/0091270010389471-BIB16|cit16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.5694\/j.1326-5377.1986.tb128359.x","article-title":"Drug interactions with oral contraceptive preparations","volume":"17","author":"Shenfield","year":"1986","journal-title":"Med J Aust"},{"key":"10.1177\/0091270010389471-BIB17|cit17","unstructured":"World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects http:www.wma.neten30publications10policiesb3index.html"},{"key":"10.1177\/0091270010389471-BIB18|cit18","unstructured":"European Agency for the Evaluation of Medicinal Products, International Conference on Harmonisation-World Health Organization. Guideline for Good Clinical Practice [EMEA Web site] http:www.ema.europa.eupdfshumanich013595en.pdf"},{"key":"10.1177\/0091270010389471-BIB19|cit19","volume-title":"Guidance for Industry. In vivo drug metabolism\/drug interaction studies-study design, data analysis, and recommendations for dosing and labeling","author":"Food and Drug Administration (FDA).","year":"November 1999"},{"key":"10.1177\/0091270010389471-BIB20|cit20","unstructured":"European Medicines Agency (EMEA). Note for guidance on the investigation of drug interactions 17 December 1997 http:www.ema.europa.eupdfshumanewp056095en.pdf"},{"issue":"suppl 2","key":"10.1177\/0091270010389471-BIB21|cit21","article-title":"Effects of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women","volume":"9","author":"Kothare","year":"2007","journal-title":"AAPS J"},{"key":"10.1177\/0091270010389471-BIB22|cit22","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.contraception.2007.10.009","article-title":"Novel ethinyl estradiol-beta-cyclodextrin clathrate formulation does not influence the relative bioavailability of ethinyl estradiol or coadministered drospirenone","volume":"77","author":"Blode","year":"2008","journal-title":"Contraception"},{"key":"10.1177\/0091270010389471-BIB23|cit23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.contraception.2009.04.011","article-title":"Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity","volume":"80","author":"Edelman","year":"2009","journal-title":"Contraception"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270010389471","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1177\/0091270010389471\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T08:58:05Z","timestamp":1657789085000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1177\/0091270010389471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"URL":"https:\/\/doi.org\/10.1177\/0091270010389471","relation":{},"ISSN":["0091-2700"],"issn-type":[{"value":"0091-2700","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}